SFS
EGRX

Sowell Financial Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Sowell Financial Services’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-530
Closed -$30K – 2685
2019
Q3 		$30K Buy
+530
New +$29.8K ﹤0.01% 1150

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HEC
Hudson Executive Capital New York $50.9M AUM 22.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Sowell Financial Services's EGRX Position: Q4 2019 in Review

Sowell Financial Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2019, closing a stake of 530 shares — an estimated $30K sold.

Sowell Financial Services first reported a position in EGRX in Q3 2019 and held it in 1 quarter. The position peaked at $30K in Q3 2019. 176 funds tracked by Wall St. Rank hold EGRX as of Q4 2019.

  • Sowell Financial Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Sowell Financial Services sold 530 Eagle Pharmaceuticals, Inc. shares in Q4 2019, an estimated $30K.
  • Sowell Financial Services first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2019 and held it in 1 quarter.
  • Sowell Financial Services's Eagle Pharmaceuticals, Inc. position peaked at $30K in Q3 2019.
  • 176 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2019.

Based on Sowell Financial Services's 13F filing for Q4 2019, filed 7 Feb 2020.